ISRCTN70794078进行中（未招募）4 期
COrticosteroids for COVID-19 induced loss of Smell (COCOS trial)
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 115
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36384737/ (added 18/11/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Recent COVID-19 infection (<3 months), confirmed with a positive test
- •2. Persistent loss of smell after 1 month, objectified by threshold-discrimination-identification (TDI) <30.5 on Sniffin’ Stick test
- •3. Age 18 years or older, capable of giving informed consent
排除标准
- •1. Pre-existing olfactory disorders
- •2. Chronic rhinitis or rhinosinusitis (with or without nasal polyps)
- •3. Pregnancy
- •4. Corticosteroids (nasal, oral or intravenously) in last month
- •5. Contra-indications of steroid use:
- •5.1. Insulin dependent diabetes mellitus
- •5.2. Ulcus pepticum
研究者
相似试验
尚未招募
不适用
COrticosteroids for COVID-19 induced loss of Smelloss of smell after COVID-19 infectionNL-OMON28709MC Utrecht116
进行中（未招募）
1 期
Corticosteroids for loss of smell by COVID-19 infection – COCOS trialEUCTR2021-004021-71-NLniversity Medical Center Utrecht116
已完成
4 期
COrticosteroids for COVID-19 induced loss of Smell - COCOS trial (AMENDMENT)AnosmiaNL-OMON54199Academisch Medisch Centrum111
Unknown
不适用
Clinical Treatment Research of COVID-19-related Olfactory DysfunctionOlfactory DysfunctionNCT05421195Eye & ENT Hospital of Fudan University124
已完成
2 期
Smell in Covid-19 and Efficacy of Nasal TheophyllineCovid19Olfactory DisorderCovid-19 PandemicSARS-CoV-2 InfectionHyposmiaAgeusiaHypogeusiaAnosmiaNCT04789499Washington University School of Medicine51